Cargando…
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
BACKGROUND: [(18)F]THK5351 is a tau positron emission tomography tracer that has shown promise in quantifying tau distribution in tauopathies such as Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). However, the interpretation of [(18)F]THK5351 uptake has been shown to be conf...
Autores principales: | Ng, Kok Pin, Therriault, Joseph, Kang, Min Su, Struyfs, Hanne, Pascoal, Tharick A, Mathotaarachchi, Sulantha, Shin, Monica, Benedet, Andrea L, Massarweh, Gassan, Soucy, Jean-Paul, Neto, Pedro Rosa, Gauthier, Serge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889764/ https://www.ncbi.nlm.nih.gov/pubmed/31795034 http://dx.doi.org/10.1016/j.nicl.2019.102091 |
Ejemplares similares
-
Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
por: Ng, Kok Pin, et al.
Publicado: (2017) -
Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018) -
Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
por: Pascoal, Tharick A., et al.
Publicado: (2020) -
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018) -
[(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy
por: Brendel, Matthias, et al.
Publicado: (2018)